Results 231 to 240 of about 17,756 (301)

INCIDENCE AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION AMONG PATIENTS WITH AND WITHOUT OBSTRUCTIVE SLEEP APNEA: A National Cohort Study. [PDF]

Retina
Blazes M, Ngadisastra C, Li PR, Lee CS, Lee JS, See LC, Lin KK.   +6 more
europepmc   +1 more source

CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers-a register-based case-crossover study. [PDF]

Sci Rep
Leander K, Dahl ML, Vikström M, Möller J, Söderberg-Löfdal K.   +4 more
europepmc   +1 more source

Antiplatelet, Anticoagulant, and Fibrinolytic Activity of Orchids: A Review. [PDF]

Molecules
Fernández-Rojas B, López-Pérez A, Lagunez-Rivera L, Solano R, Bernal-Martínez AK, Majluf-Cruz A, Hernández-Juárez J.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39.

Bioorganic chemistry (Print), 2023
Ticlopidine is an antithrombotic prodrug of the thienotetrahydropyridine family. For platelet inhibition it has to undergo oxidative ring-opening by cytochrome P450 enzymes.
Chunyang Bi, Laura Schäkel, Salahuddin Mirza, Katharina Sylvester, J. Pelletier, Sang-Yong Lee, Thanigaimalai Pillaiyar, J. Sévigny, C. Müller   +8 more
semanticscholar   +1 more source

Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.

Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy, 2019
BACKGROUND The aim of this study is to evaluate the use of Aspirin, Pycnogenol®, ticlopidine, and sulodexide to reduce the incidence of new RTV (retinal vein thrombosis) after a first episode.
G. Belcaro, M. Dugall, Hugh D Bradford, M. Cesarone, B. Feragalli, C. Gizzi, R. Cotellese, Shu Hu, P. Rodriguez, M. Hosoi   +9 more
semanticscholar   +1 more source

Ticlopidine-Induced Lupus

JCR: Journal of Clinical Rheumatology, 2001
Ticlopidine is a widely used drug for prevention of stroke and other serious vascular events with a multitude of possible side effects. An increasing number of drugs are being recognized as the triggering agents of drug-induced lupus. We describe three patients in whom the etiologic connection between ticlopidine and lupus was supported by the ...
Alexandra Balbir-Gurman, Daniel Schapira, Ronit Sevilia, Yolanda Braun-Moscovici, Abraham Menahem Nahir   +4 more
openaire   +3 more sources

HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors.

Chemical Research in Toxicology, 2018
The HLA class I allele HLA-A*33:03 is a risk factor for ticlopidine-induced liver injury. Herein, we show HLA class I-restricted ticlopidine-specific CD8+ T-cell activation in healthy donors expressing HLA-A*33:03.
Toru Usui, A. Tailor, L. Faulkner, Xiaoli Meng, J. Farrell, A. Daly, G. Dear, B. Park, D. Naisbitt   +8 more
semanticscholar   +1 more source